Preservative-free triamcinolone acetonide injectable suspension versus "traditional" triamcinolone preparations: Impact of aggregate size on retinal biocompatibility

Retina

Volumn 31, Issue 10, 2011, Pages 2050-2057

  Spitzer, Martin S ^a   Mlynczak, Tomasz ^a,b   Schultheiss, Maximilian ^a   Rinker, Kathrin ^a   Yoeruek, Efdal ^a   Petermeier, Katrin ^a   Januschowski, Kai ^a   Szurman, Peter ^a  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^b WROCLAW MEDICAL UNIVERSITY   (Poland)

Author keywords

Intravitreal injection; Kenalog; Ocular biocompatibility; Triamcinolone; Triamcinolone acetonide; Triamcinolone crystals; Triamcinolone sediments; Triesence

Indexed keywords

TRIAMCINOLONE ACETONIDE;

ANIMAL CELL; ARTICLE; BIOCOMPATIBILITY; CELL CULTURE; CELL PROLIFERATION; CELL VIABILITY; CYTOTOXICITY; ENZYME LINKED IMMUNOSORBENT ASSAY; NONHUMAN; RAT; RETINA CELL; RETINA GANGLION CELL; SEDIMENTATION;

CELL SURVIVAL; CELLS, CULTURED; CRYSTALLIZATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; PARTICLE SIZE; PHARMACEUTICAL PREPARATIONS; PRESERVATIVES, PHARMACEUTICAL; RETINAL GANGLION CELLS; RETINAL PIGMENT EPITHELIUM; TRIAMCINOLONE ACETONIDE;

EID: 80055095810     PISSN: 0275004X     EISSN: 15392864     Source Type: Journal    
DOI: 10.1097/IAE.0b013e318214d076     Document Type: Article

References (32)

1. Machemer R, Sugita G, Tano Y. Treatment of intraocular proliferations with intravitreal steroids. Trans Am Ophthalmol Soc 1979;77:171-180. (Pubitemid 10072805)
2. Tano Y, Chandler D, Machemer R. Treatment of intraocular proliferation with intravitreal injection of triamcinolone acetonide. Am J Ophthalmol 1980;90:810-816. (Pubitemid 11199134)
3. Antcliff RJ, Spalton DJ, Stanford MR, et al. Intravitreal triamcinolone for uveitic cystoid macular edema: an optical coherence tomography study. Ophthalmology 2001;108: 765-772. (Pubitemid 32238474)
4. Martidis A, Duker JS, Greenberg PB, et al. Intravitreal triamcinolone for refractory diabetic macular edema. Ophthalmology 2002;109:920-927. (Pubitemid 34465226)
5. Jonas JB, Kreissig I, Sofker A, Degenring RF. Intravitreal injection of triamcinolone for diffuse diabetic macular edema. Arch Ophthalmol 2003;121:57-61. (Pubitemid 36401766)
6. Danis RP, Ciulla TA, Pratt LM, Anliker W. Intravitreal triamcinolone acetonide in exudative age-related macular degeneration. Retina 2000;20:244-250. (Pubitemid 30436775)
7. Jonas JB, Degenring RF, Kreissig I, et al. Exudative age-related macular degeneration treated by intravitreal triamcinolone acetonide. A prospective comparative nonrandomized study. Eye 2005;19:163-170. (Pubitemid 40326161)
8. Jonas JB, Hayler JK, Soüfker A, Panda-Jonas S. Intravitreal injection of crystalline cortisone as adjunctive treatment of proliferative diabetic retinopathy. Am J Ophthalmol 2001;131: 468-471. (Pubitemid 32273433)
9. Jonas JB, Hayler JK, Panda-Jonas S. Intravitreal injection of crystalline cortisone as adjunctive treatment of proliferative vitreoretinopathy. Br J Ophthalmol 2000;84: 1064-1067.
10. Munir WM, Pulido JS, Sharma MC, Buerk BM. Intravitreal triamcinolone for treatment of complicated proliferative diabetic retinopathy and proliferative vitreoretinopathy. Can J Ophthalmol 2005;40:598-604. (Pubitemid 41564963)
11. Peyman GA, Cheema R, Conway MD, Fang T. Triamcinolone acetonide as an aid to visualization of the vitreous and the posterior hyaloids during pars plana vitrectomy. Retina 2000; 20:554-555. (Pubitemid 32001537)
12. Burk SE, da Mata AP, Snyder ME, et al. Visualizing vitreous using Kenalog suspension. J Cataract Refract Surg 2003;29: 645-651. (Pubitemid 36418002)
13. Yamakiri K, Ushino E, Kimura K, Sakamoto T. Intracameral triamcinolone helps to visualize and remove the vitreous body in anterior chamber in cataract surgery. Am J Ophthalmol 2004;138:650-652. (Pubitemid 39420498)
14. Sonoda KH, Sakamoto T, Enaida H, et al. Residual vitreous cortex after surgical posterior vitreous separation visualized by intravitreous triamcinolone acetonide. Ophthalmology 2004; 111:226-230. (Pubitemid 38183219)
15. Yamamoto N, Ozaki N, Murakami K. Triamcinolone acetonide facilitates removal of the epiretinal membrane and separation of the residual vitreous cortex in highly myopic eyes with retinal detachment due to a macular hole. Ophthalmologica 2004;32:56-59.
16. Yeung CK, Chan KP, Chiang SWY, et al. The toxic and stress responses of cultured human retinal pigment epithelium (ARPE19) and human glial cells (SVG) in the presence of triamcinolone. Invest Ophthalmol Vis Sci 2003; 44:5293-5300. (Pubitemid 37475401)
17. Szurman P, Kaczmarek R, Spitzer MS, et al. Differential toxic effect of dissolved triamcinolone and its crystalline deposits on cultured human retinal pigment epithelium (ARPE19) cells. Exp Eye Res 2006;83:584-592. (Pubitemid 43902780)
18. Szurman P, Sierra A, Kaczmarek R, et al. Different biocompatibility of crystalline triamcinolone deposits on retinal cells in vitro and in vivo. Exp Eye Res 2007;85:44-53. (Pubitemid 47017266)
19. Dyer D, Callanan D, Bochow T, et al. Clinical evaluation of the safety and efficacy of preservative-free triamcinolone (Triesence- [triamcinolone acetonide injectable suspension] 40 mg/ml) for visualization during pars plana vitrectomy. Retina 2009;29:38-45.
20. Hernaez-Ortega MC, Soto-Pedre E. A simple and rapid method for purification of triamcinolone acetonide suspension for intravitreal injection. Ophthalmic Surg Lasers Imaging 2005; 35:350-351.
21. Lee B, Litt M, Buchsbaum G. Rheology of the vitreous body. Part I: Viscoelasticity of human vitreous. Biorheology 1992; 29:521-533. (Pubitemid 23104936)
22. Lee B, Litt M, Buchsbaum G. Rheology of the vitreous body: Part 2. Viscoelasticity of bovine and porcine vitreous. Biorheology 1994;31:327-338. (Pubitemid 24276118)
23. Stefaánsson E. Physiology of vitreous surgery. Graefes Arch Clin Exp Ophthalmol 2009;247:147-163.
24. Nelson ML, Tenant MT, Sivalingam A, et al. Infectious and presumed non-infectious endophthalmitis after intravitreal triamcinolone acetonide injection. Retina 2003;23:686-691. (Pubitemid 37315056)
25. Chang YS, Wu CL, Tseng SH, et al. Cytotoxicity of triamcinolone acetonide on human retinal pigment epithelial cells. Invest Ophthalmol Vis Sci 2007;48:2792-2798.
26. Szurman P, Kaczmarek R, Jaissle GB, et al. Influence of different purification techniques on triamcinolone yield and particle size spectrum. Graefes Arch Clin Exp Ophthalmol 2007;245:689-696. (Pubitemid 46951235)
27. Haller JA. Intraocular Steroids in the Office. New formulations offer preservative-free triamcinolone without relying on compounding pharmacies. Retin Phys 2009;1:45-47.
28. Wiedmann TS, Bhatia R, Wattenberg LW. Drug solubilization in lung surfactant. J Control Release 2000;65:43-47. (Pubitemid 30122913)
29. Schlaegel TF Jr, Wilson FM. Accidental intraocular injection of depot corticosteroids. Trans Am Acad Ophthalmol Otolaryngol 1978;78:847.
30. Kozak I, Cheng L, Mendez T, et al. Evaluation of the toxicity of subretinal triamcinolone acetonide in rabbits. Retina 2006;26: 811-817. (Pubitemid 44386105)
31. Moshfeghi AA, Nugent AK, Nomoto H, et al. Triamcinolone acetonide preparations: impact of crystal size on in vitro behavior. Retina 2009;29:689-698.
32. Migon R, Lin T, Zacharias L, et al. Pharmacokinetics, pharmacodynamics, and visual dissolution rates of three forms of triamcinolone acetonide (TA) in rabbits. Invest Ophthalmol Vis Sci 2010;A4504.